Passion to deliver our commitments

AdreView MIBG 123

The AdreView MIBG can be labeled with either I 131 or I 123. The 159 keV gamma energy of I 123 is more suitable for imaging than the 360keV photons of I 131 and the difference in terms of radiation burden permits to inject higher activities of AdreView MIBG – I 123. Furthermore, results with AdreView MIBG – I 123 are usually available within 24 H whereas with AdreView MIBG – I 131 delayed images may be required for optimal target to background ratios. Theoretical considerations and clinical experience indicate that the I123 labeled agent is to be considered the radiopharmaceutical of choice and it has a more favorable Dosimetry and provides better image quality.

Indications:

Oncology indications :
- Detection , localization , staging and follow up of neuroendocrine tumors and their metastasis
- Study of tumor uptake and residence time in order to decide and plan a treatment with high activities of radiolabelled mIBG
- Evaluation of tumor response to therapy
Non Oncology indications
- Functional studies of the adrenal medulla
- Sympathetic innervations of the myocardium
- Salivary glands and lungs
- Movement disorders